Journal of Human Genetics and Genomics

Published by: Kowsar
Crossmark

Rs214101 Variation of NUCB2/Nesfatin-1 Gene: Effects on Metabolic Parameters Independent of Type 2 Diabetes or Obesity in Coronary Artery Disease

Fatih Yanar 1 , Bengu Tokat 2 , Zehra Bugra 3 , Oguz Ozturk 1 and Hulya Yilmaz-Aydogan 1 , *
Authors Information
1 Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Capa, Istanbul, Turkey
2 Department of Medical Biology, Istinye University School of Medicine, Istanbul, Turkey
3 Department of Cardiology, Istanbul University School of Medicine, Istanbul, Turkey
Article information
  • Journal of Human Genetics and Genomics: July 2018, 2 (1); e80059
  • Published Online: July 10, 2017
  • Article Type: Research Article
  • Received: June 10, 2017
  • Accepted: July 25, 2017
  • DOI: 10.5812/jhgg.80059

How to Cite: Yanar F, Tokat B, Bugra Z, Ozturk O, Yilmaz-Aydogan H. Rs214101 Variation of NUCB2/Nesfatin-1 Gene: Effects on Metabolic Parameters Independent of Type 2 Diabetes or Obesity in Coronary Artery Disease, J Human Gen Genom. 2018 ; 2(1):e80059. doi: 10.5812/jhgg.80059.

Abstract
Copyright © 2017, Journal of Human Genetics and Genomics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Oh IS, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-12. doi: 10.1038/nature05162. [PubMed: 17036007].
  • 2. Barnikol-Watanabe S, Gross NA, Gotz H, Henkel T, Karabinos A, Kratzin H, et al. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol Chem Hoppe Seyler. 1994;375(8):497-512. doi: 10.1515/bchm3.1994.375.8.497. [PubMed: 7811391].
  • 3. Shimizu H, Oh IS, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology. 2009;150(2):662-71. doi: 10.1210/en.2008-0598. [PubMed: 19176321].
  • 4. Beckers S, Zegers D, Van Gaal LF, Van Hul W. The role of the leptin-melanocortin signalling pathway in the control of food intake. Crit Rev Eukaryot Gene Expr. 2009;19(4):267-87. doi: 10.1615/CritRevEukarGeneExpr.v19.i4.20. [PubMed: 19817705].
  • 5. Zegers D, Beckers S, Mertens IL, Van Gaal LF, Van Hul W. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab. 2011;103(3):282-6. doi: 10.1016/j.ymgme.2011.03.007. [PubMed: 21459029].
  • 6. Platt DE, Ghassibe-Sabbagh M, Youhanna S, Hager J, Cazier JB, Kamatani Y, et al. Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography. J Thromb Thrombolysis. 2015;39(1):15-22. doi: 10.1007/s11239-014-1069-2. [PubMed: 24788070].
  • 7. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486. [PubMed: 11368702].
  • 8. Emerging Risk Factors C, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. doi: 10.1001/jama.2009.1619. [PubMed: 19903920]. [PubMed Central: PMC3284229].
  • 9. Prospective Studies C, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. doi: 10.1016/S0140-6736(07)61778-4. [PubMed: 18061058].
  • 10. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation. 1998;97(21):2099-100. doi: 10.1161/01.CIR.97.21.2099. [PubMed: 9626167].
  • 11. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring). 2007;15(12):2875-88. doi: 10.1038/oby.2007.342. [PubMed: 18198293].
  • 12. Wang R, Wang J, Wan X. Association of the Polymorphism in Nucleobindin 2 Gene and the Risk of Metabolic Syndrome. Genet Test Mol Biomarkers. 2016;20(1):49-52. doi: 10.1089/gtmb.2015.0194. [PubMed: 26624852].
  • 13. Taskin MI, Eser B, Adali E, Kara H, Cuce C, Hismiogullari AA. NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(1):46-50. doi: 10.3109/09513590.2015.1081682. [PubMed: 26369257].
  • 14. Chen YY, Chan RM, Tan KM, Poh LK, Loke KY, Wang JP, et al. The association of a nucleobindin 2 gene (NUCB2) variant with childhood adiposity. Gene. 2013;516(1):48-52. doi: 10.1016/j.gene.2012.12.017. [PubMed: 23266808].
  • 15. Khalili S, Khaniani M, Aghamohammdzade N, Akbarzadeh A, Derakhshan S. The Association of Nucleobindin 2 Gene (NUCB2) Variants with Type 2 Diabetes Mellitus Among Iranian Azeri-Turkish Population. Biosci Biotechnol Res Asia. 2016;13(3):1821-8. doi: 10.13005/bbra/2335.
  • 16. Ding S, Qu W, Dang S, Xie X, Xu J, Wang Y, et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med Sci Monit. 2015;21:987-91. doi: 10.12659/MSM.892611. [PubMed: 25841171]. [PubMed Central: PMC4396685].
  • 17. Dai H, Li X, He T, Wang Y, Wang Z, Wang S, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2013;46:167-71. doi: 10.1016/j.peptides.2013.06.006. [PubMed: 23806888].
  • 18. Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, et al. Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci. 2015;15(3):57-63. doi: 10.17305/bjbms.2015.432. [PubMed: 26295295]. [PubMed Central: PMC4594327].
  • 19. Worlg Health Organization . The top 10 causes of death. 2017, [updated January 2017]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
  • 20. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-9. doi: 10.1001/jama.289.1.76. [PubMed: 12503980].
  • 21. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-81. [PubMed: 12020339].
  • 22. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009;297(2):R330-6. doi: 10.1152/ajpregu.90867.2008. [PubMed: 19474390]. [PubMed Central: PMC2724238].
  • 23. Angelone T, Filice E, Pasqua T, Amodio N, Galluccio M, Montesanti G, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci. 2013;70(3):495-509. doi: 10.1007/s00018-012-1138-7. [PubMed: 22955491].
  • 24. Ensembl genome browser. 2017. Available from: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core.
  • 25. Bergmann K, Kretowicz M, Manitius J, Sypniewska G. Gender differences in association of serum nesfatin-1 with selected metabolic risk factors in normoglycemic subjects: A preliminary study. J Diabetes. 2015;7(3):433-4. doi: 10.1111/1753-0407.12189. [PubMed: 24981793].
  • 26. Hofmann T, Elbelt U, Ahnis A, Rose M, Klapp BF, Stengel A. Sex-specific regulation of NUCB2/nesfatin-1: Differential implication in anxiety in obese men and women. Psychoneuroendocrinology. 2015;60:130-7. doi: 10.1016/j.psyneuen.2015.06.014. [PubMed: 26143537].
  • 27. Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet beta- and MIN6 cells. J Endocrinol. 2011;208(3):R9-R16. doi: 10.1530/JOE-10-0492. [PubMed: 21224288].
  • 28. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet beta-cells. Endocr J. 2011;58(4):305-13. doi: 10.1507/endocrj.K11E-056. [PubMed: 21325742].
  • 29. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159(1-3):72-7. doi: 10.1016/j.regpep.2009.11.003. [PubMed: 19896982].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments